Given the synergism in robustly inducing thyroid gene expression and radioiodine uptake in thyroid cancer cells by simultaneously inhibiting HDAC and the MAP kinase and PI3K/Akt pathways [13], in the present study we tested the potential of this novel therapeutic strategy to induce NIS expression for radioiodine uptake in an extended panel of non-thyroid cancer cells. The gene discussed is HDAC9; the disease is thyroid gland carcinoma.